Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study.

Markus Wallwiener, Naiba Nabieva, Manuel Feisst, Tanja Fehm, Johann de Waal, Mahdi Rezai, Bernd Baier, Gerold Baake, Hans-Christian Kolberg, Martin Guggenberger, Mathias Warm, Nadia Harbeck, Rachel Wuerstlein, Jörg-Uwe Deuker, Peter Dall, Barbara Richter, Grischa Wachsmann, Cosima Brucker (Co-author), Jan Willem Siebers, Milos PopovicThomas Kuhn, Christopher Wolf, Hans-Walter Vollert, Georg-Peter Breitbach, Wolfgang Janni, Robert Landthaler, Andreas Kohls, Daniela Rezek, Thomas Noesselt, Gunnar Fischer, Stephan Henschen, Thomas Praetz, Volker Heyl, Thorsten Kühn, Thomas Krauss, Christoph Thomssen, Andre Hohn, Hans Tesch, Christoph Mundhenke, Alexander Hein, Claudia Rauh, Christian M Bayer, Katja Schmidt, Erik Belleville, Sara Y Brucker, Peyman Hadji, Matthias W Beckmann, Diethelm Wallwiener, Sherko Kümmel, Andreas Hartkopf, Peter A Fasching

Research output: Contribution to journalOriginal Articlepeer-review

5 Citations (Web of Science)
Original languageEnglish
Pages (from-to)611
JournalBMC CANCER
Volume19
Issue number1
DOIs
Publication statusPublished - 2019

Keywords

  • ADJUVANT HORMONAL-THERAPY
  • ENDOCRINE THERAPY
  • CLINICAL-PRACTICE
  • ADHERENCE
  • DISCONTINUATION
  • GUIDELINES
  • TAMOXIFEN
  • TRIAL

Cite this